

Applicants note that claim 17 is also directed to a method of use and should be included in Group I and assume that the Examiner means to include claim 17 in Group I

Applicants elect hereby claims 10-15 directed to a method of treating diabetic diseases.

The Examiner further requires the election of a single compound from the base Formula (I).

Applicants hereby elects compound of Example 43 (pages 43-44 of the specification, wherein n is 2, z is $-NR^{2a}R^{2b}$ (wherein R^{2a} and R^{2b} are methyl), X¹ is nitrogen and X² is a methine group.

REMARKS

Applicant is making this election without traverse in order to expedite the prosecution of this application.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: August 28, 2006

By:



Maria C.H. Lin
Registration No. 29,323

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800
(212) 751-6849

Telephone
Facsimile